1. "Gastrointestinal Oncology Service"
Formats
  1. Journal Article (2302)
  2. Meeting Abstract (1841)
  3. Review (139)
  4. Book Section (123)
  5. Editorial (93)
  6. Guidelines (36)
  7. Correspondence (33)
  8. Conference Paper (23)
  9. Miscellaneous (21)
  10. Research Letter (17)
  11. Book Whole (12)
Groups
  1. Gastrointestinal Oncology Service (4640)
  2. Solid Tumor Oncology Division (4640)
  3. Department of Medicine (4638)
  4. Center for Pancreatic Cancer Research (2270)
  5. Surgery (1040)
  6. Survivorship Research (992)

More Groups

People
  1. Leonard Saltz (790)
  2. Eileen O'Reilly (780)
  3. Ghassan Abou-Alfa (568)
  4. Nancy Kemeny (543)
  5. David Kelsen (537)
  6. David Ilson (433)

More People

Years
  1. 2025 (118)
  2. 2024 (307)
  3. 2023 (362)
  4. 2022 (346)
  5. 2021 (345)
  6. 2020 (326)

More Years

Publications
  1. Journal of Clinical Oncology (1276)
  2. Annals of Oncology (320)
  3. Annals of Surgical Oncology (140)
  4. Cancer (127)
  5. Clinical Cancer Research (107)
  6. Cancer Research (94)

More Publications

Publishers
  1. American Society of Clinical Oncology (1355)
  2. Oxford University Press (447)
  3. Elsevier Inc. (404)
  4. Springer (310)
  5. American Association for Cancer Research (279)
  6. Wiley Blackwell (239)

More Publishers

Results (4640)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Unique genomic alterations and microbial profiles identified in patients with gastric cancer of African, European, and Asian Ancestry: A novel path for precision oncology
    Conference Paper

    Abate, M.; Walch, H.; Arora, K.; Vanderbilt, C. M.; Fei, T.; Drebin, H.; Shimada, S.; Maio, A.; Kemel, Y.; Stadler, Z. K.; more...
    Lippincott Williams & Wilkins (2023)

    Fulltext@MSK | Save
  • Adagrasib in advanced solid tumors harboring a KRAS(G12C) mutation
    Journal Article

    Bekaii-Saab, T. S.; Yaeger, R.; Spira, A. I.; Pelster, M. S.; Sabari, J. K.; Hafez, N.; Barve, M.; Velastegui, K.; Yan, X.; Shetty, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • STAR-221: A randomized, open-label, multicenter, phase 3 trial of domvanalimab, zimberelimab, and chemotherapy versus nivolumab and chemotherapy in previously untreated, locally advanced, unresectable or metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma
    Meeting Abstract

    Klempner, S. J.; Shitara, K.; Sison, A.; Scott, J.; Wishengrad, D.; Ronayne, J.; Rhee, J.; Mitra, S.; Nuyten, D. S. A.; Janjigian, Y. Y.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 1b, open-label, two-part safety, tolerability, and efficacy study of a soluble beta-glucan (odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX-1140) in patients with metastatic pancreatic adenocarcinoma whose disease did not progress during first-line (1L) chemotherapy
    Meeting Abstract

    O'Hara, M. H.; Wattenberg, M. M.; Garrido-Laguna, I.; O'Reilly, E. M.; Yellin, M. J.; Keler, T.; Gargano, M. A.; Niles, N.; Drees, J.; Bose, N.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Alliance A021804: A prospective, multi-institutional phase II trial evaluating temozolomide versus temozolomide and olaparib for advanced pheochromocytoma and paraganglioma
    Meeting Abstract

    Del Rivero, J.; Perez, K.; Geyer, S. M.; Khalil, M. F.; Vijendran, A.; Kordaris-Corkill, A.; Shergill, A.; Spencer, K. R.; Soares, H. P.; Lopez, C. D.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase IIa/IIb, open-label trial of BI 907828, an MDM2–p53 antagonist, in patients with locally advanced/metastatic biliary tract carcinoma or pancreatic ductal adenocarcinoma: Brightline-2
    Meeting Abstract

    Goyal, L.; Harding, J. J.; Ueno, M.; Lamarca, A.; Macarulla, T.; Yamamoto, N.; Hu, J.; Teufel, M.; Maerten, A.; Vogel, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA 1/2+) pathogenic variants: SWOG S2001
    Meeting Abstract

    Chung, V.; Guthrie, K. A.; Pishvaian, M. J.; Reiss, K. A.; Lowy, A. M.; Sohal, D.; Colby, S.; Sharon, E.; Allegra, C. J.; O'Reilly, E. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Alliance A021806: A phase III trial evaluating perioperative versus adjuvant therapy for resectable pancreatic cancer
    Meeting Abstract

    Chawla, A.; Shi, Q.; Ko, A. H.; Beg, S.; Varghese, A. M.; Behrman, S. W.; Bloomston, M.; Ahmed, F. S.; Frankel, W. L.; Dixon, J. G.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Autologous cytotoxic T-cell receptor T cell therapy (SCG101) against hepatitis B surface antigen phase I/II trial for patients with advanced hepatitis B-related hepatocellular carcinoma
    Meeting Abstract

    Abou-Alfa, G. K.; Yong, W. P.; Chang, S. L.; Fan, J.; Toh, H. C.; Yau, T.; Choo, S.; Wang, J.; Kusuma, N.; Ma, C.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first line treatment in HER2+ metastatic colorectal cancer
    Meeting Abstract

    Bekaii-Saab, T. S.; Van Cutsem, E.; Tabernero, J.; Siena, S.; Yoshino, T.; Nakamura, Y.; Raghav, K. P. S.; Cercek, A.; Heinemann, V.; Adelberg, D. E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save